RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $13
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $12 to $13.
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $12 to $13.